Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia

Blood

Volumn 91, Issue 5, 1998, Pages 1742-1748

  Consoli, Ugo ^a   El Tounsi, Iman ^b   Sandoval, Alex ^b   Snell, Virginia ^b   Kleine, Hans Dieter ^b   Brown, Wendy ^b   Robinson, Johnnie R ^b   DiRaimondo, Francesco ^b   Plunkett, William ^b   Andreeff, Michael ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE PHOSPHATE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DNA CONTENT; DNA REPAIR; DNA STRAND BREAKAGE; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

EID: 0032030689     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.5.1742     Document Type: Article

References (46)

1. Keating MJ, O'Brian S, Robertson LE, Kantarjian H, Dimopulos M, McLaughlin P, Cabanillas F, Gregoire V, Ying-Yang L, Gandhi V, Estey E, Plunkett W: The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 14:11, 1994
2. Plunkett W, Gandhi V, Huang P, Robertson LE, Ying-Yang L, Gregoire V, Estey E, Keating MJ: Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol20:2, 1993
3. Keating MJ: Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 17:49, 1990
4. Hochster H, Cassileth P: Fludarabine phosphate therapy of non-Hodgkin's lymphoma. Semin Oncol 17:63, 1990
5. Kantarjian H, Redman RJ, Keating MJ: Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 17:66, 1990
6. Keating MJ, Kantarjian H, Talpaz M, Redman RJ, Koller H, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19, 1989
7. Wijermans PW, Gerrits WBJ, Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292, 1993
8. Boldt DH, Von Hoff DD, Kuhn JH, Hersh M: Effects on human peripheral lymphocytes of in vivo administration of 9-β-D-arabinofura-nosyl-2fluoroadenine-5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 44:4661, 1984
9. Burrows PD, Kearney JF, Schroeder HWJ, Cooper MD: Normal B lymphocyte differentiation. Baillieres Clin Haematol 6:785, 1993
10. Peller S, Kaufman S: Decreased CD45RA T cells in B-cell chronic lymphatic leukemia patients: Correlation with disease stage. Blood 78:1569, 1991
11. Catovsky D, Milliani E, Okos A, Galton D: Clinical significance of T cells in chronic lymphocytic leukemia. Lancet 2:751, 1974
12. Bergui L, Gregoretti MG, Caligaris-Cappio F: Cyclosporin A in the treatment of B-chronic lymphocytic leukemia. Leukemia 8:1245, 1994
13. Van Den Neste E, Maerevoet M, Martiat P, Ferrant A, Delannoy A, Michaux JL: Cyclosporine A has only marginal antileukemic activity in refractory chronic lymphocytic leukemia. Leukemia 9:1102, 1995
14. Larsson R, Jonsson B, Csoka K, Kristensen J, Nilsson K, Nygren P: Selective cytotoxic activity of cyclosporins against tumor cells from patients with B cell chronic lymphocytic leukemia. Eur J Pharmacol 228:237, 1992
15. Shevach EM: The effect of cyclosporin A on the immune system. Ann Rev Immunol 3:397, 1985
16. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H: Involvement of p-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-γ in normal human T lymphocytes. Blood 88:1747, 1996
17. Schmid M, Merk B, Porzsolt F: Cyclosporin A inhibits cytokineinduced proliferation in B-chronic lymphocytic leukemia. Leuk Lymphoma 15:317, 1994
18. Gorczyca W, Gong J, Darzynkiewicz Z: Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assay. Cancer Res 53:1945, 1993
19. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol 29:152, 1988
20. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS: Clinical staging of chronic lymphocytic leukemia. Blood 46:219, 1975
21. Schwartz A, Fernandez-Repollet E: Development of clinical standards for flow cytometry. Ann NY Acad Sci 677:28, 1993
22. Lavabre-Bertrand T, Janossy G, Ivory K, Peter R, Seeker-Walker L, Porwit-MacDonald A: Leukemia associated changes identified by quantitative flow cytometry. I. CD10 expression. Commun Clin Cytometry 18:533, 1994
23. Danhauser L, Plunkett W, Keating M, Cabanillas F:9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18:142, 1986
24. DiRaimondo F, Palumbo GA, Romeo MA, Cacciola E, Milone G, Impera S, Giustolisi R, Cacciola E: In vitro sensitivity of B-CLL cells to fludarabine and interferons. Leuk Lymphoma 17:449, 1995
25. Gandhi V, Kemena A, Keating MJ, Plunkett W: Cellular pharmacology of fludarabine triphosphate in CLL cells during fludarabine therapy. Leuk Lymphoma 10:45, 1993
26. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G: Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 9:1191, 1995
27. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D: Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 4:371, 1993
28. Chikkappa G, Pasquale D, Zarrabi MH, Weiler RJ, Divakara M, Tsan MF: Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chrome lymphocytic leukemia. Am J Hematol 41:5, 1992
29. Emilia G, Messora C, Bensi L, Luppi M: The use of cyclosporin-A in the treatment of B-chronic lymphocytic leukemia. Leukemia 9:357, 1995
30. Murayama T, Imoto S, Takahashi T, Ito M, Matokazi S, Nakagawa T: Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin-A. Cancer 69:2657, 1991
31. Schmid M, Merk B, Porzsolt F: Cyclosporin A inhibits cytokineinduced proliferation in B-chronic lymphocytic leukemia. Leuk Lymphoma 15:317, 1994
32. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC: Bcl-2 gene hypomethylation and high-level expression in B-CLL chronic lymphocytic leukemia. Blood 82:1820, 1993
33. Miyashita T, Reed JC: BCL-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407, 1992
34. Miyashita T, Reed JC: BCL-2 oncoprotein blocks chemotherapyinduced apoptosis in a human leukemia cell line. Blood 81:151, 1993
35. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80:879, 1992
36. Campana D, Coustan-Smith E, Manabe A, Buschle M, Raimondi SC, Behm FG, Ashmun R, Arico M, Biondi A, Pui CH: Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood 81:1025, 1993
37. Kitada S, Andersen J, Hines J, Rai K, Cassileth P, Reed JC: Expression of bcl-2 family genes and in vitro sensitivity to fludarabine and 2-chlorodeoxy-adenosine in B-CLL: An ECOG study. Blood 86:607a, 1995 (abstr, suppl)
38. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with induction of apoptosis and clinical outcome. Leukemia 10:456, 1996
39. Daeninck PJ, Begleiter A, Verburg L, Lee K, Williams G, Israels LG, Johnston JB: Correlation of bax, bcl-2, and mdm-2 expression with drug sensitivity in chronic lymphocytic leukemia. Blood 86:1367a, 1995 (abstr, suppl)
40. Holder MJ, Wang H, Milner AE, Casamayor M, Armitage R, Spriggs MK, Fanslow WC, MacLennan IMC, Gregory CD, Gordon J: Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of bcl-2 induction. Eur J Immunol 23:2368, 1993
41. Lomo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK: Expression of the bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Cancer Res 56:40, 1996
42. Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB: PML/RARα, a fusion protein in acute promyelocytic leukemia prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res 1:583, 1995
43. Goodacre A, Consoli U, Andreeff M: In situ identification of apoptosis with simultaneous FISH and surface markers. 47th Annual Symposium on Fundamental Cancer Research Abst B-12:88, 1994
44. Consoli U, Kleine HD, Andreeff M: Apoptosis in antigen defined hematological cell system: Correlation to cell cycle, differentiation and multidrug resistance (MDR). 47th Annual Symposium on Fundamental Cancer Research Abst B-12:88, 1994
45. Huang P, Plunkett W: Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181, 1995
46. Sandoval A, Consoli U, Plunkett W. Differential induction of apoptosis in B and T lymphocytes in response to UV radiation and fludarabine. Clin Cancer Res 2:1731, 1996